Iptacopan API is a pharmaceutical-grade oral Complement Factor B inhibitor developed for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and other complement-mediated disorders. It selectively inhibits Factor B of the alternative complement pathway, preventing excessive complement activation while preserving the classical immune response.
By targeting the proximal alternative complement pathway, Iptacopan helps reduce intravascular and extravascular hemolysis, improve hemoglobin levels, decrease transfusion requirements, and enhance quality of life in patients with complement-mediated diseases.
Manufactured under WHO-GMP-certified facilities, our Iptacopan API is produced using advanced pharmaceutical manufacturing technologies to ensure exceptional purity, stability, and batch-to-batch consistency. Every batch undergoes comprehensive analytical testing and is supplied with Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and complete regulatory documentation.
Iptacopan API is used in oral pharmaceutical formulations for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and other complement-mediated disorders.
Iptacopan selectively inhibits Complement Factor B, blocking activation of the alternative complement pathway and reducing complement-mediated destruction of red blood cells.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation with every shipment.
Yes. We supply Iptacopan API in commercial quantities with worldwide export support and customized packaging.
Get Bulk Quote via WhatsApp